BiotechTube
Third Harmonic Bio

Third Harmonic Bio

THRDPhase 1
11-50 employeesthirdharmonicbio.com

Third Harmonic Bio is pioneering a new approach to treating mast cell-driven diseases by developing highly selective, oral KIT inhibitors. The company's lead program, THB001, is in Phase 1b clinical trials for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with a pipeline targeting other mast cell-mediated conditions. Founded by experienced biotech leaders and backed by top-tier investors, the company aims to address significant unmet needs in allergy and inflammation with a precision medicine strategy.

Market Cap
$240M
Pipeline
2
drug candidates
Patents
—
Publications
—

AI Company Overview

Third Harmonic Bio is pioneering a new approach to treating mast cell-driven diseases by developing highly selective, oral KIT inhibitors. The company's lead program, THB001, is in Phase 1b clinical trials for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with a pipeline targeting other mast cell-mediated conditions. Founded by experienced biotech leaders and backed by top-tier investors, the company aims to address significant unmet needs in allergy and inflammation with a precision medicine strategy.

ImmunologyInflammationAllergy

Technology Platform

Platform for developing highly selective, oral small-molecule inhibitors of the KIT receptor tyrosine kinase, designed to precisely target mast cells for the treatment of chronic inflammatory and allergic diseases.

Pipeline

2
2 drugs in pipeline
DrugIndicationStageWatch
THB001Chronic Cold UrticariaPhase 1
THB335 single dose + Single dose placebo + THB335 fasted/fed...HealthyPhase 1

Opportunities

Significant opportunity to establish a new class of oral, targeted therapy for mast cell-driven diseases, starting with chronic urticaria.
Positive Phase 1b data could unlock expansion into larger markets like atopic dermatitis and eosinophilic esophagitis, representing a multi-billion dollar addressable market.
The oral dosing and targeted mechanism offer potential differentiation versus injectable biologics.

Risk Factors

High clinical development risk as the company's value is tied to a single lead asset.
Faces competition from established biologics and other novel KIT inhibitors in development.
Will require substantial additional capital to advance into later-stage trials, subject to market conditions.

Competitive Landscape

Competes against standard-of-care antihistamines and omalizumab in urticaria, and against other selective KIT inhibitors in development from companies like Blueprint Medicines and Cogent Biosciences. Differentiation hinges on demonstrating superior efficacy, safety, and convenience of an oral therapy targeting the mast cell root cause.